Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models

Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mech...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular medicine reports 2022-03, Vol.25 (3), Article 91
Hauptverfasser: Zhang, Jing, Sun, Bohao, Yang, Jifeng, Chen, Zhuo, Li, Zhengzheng, Zhang, Nan, Li, Hongzhi, Shen, Luxi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page
container_title Molecular medicine reports
container_volume 25
creator Zhang, Jing
Sun, Bohao
Yang, Jifeng
Chen, Zhuo
Li, Zhengzheng
Zhang, Nan
Li, Hongzhi
Shen, Luxi
description Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.
doi_str_mv 10.3892/mmr.2022.12607
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8809117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A695364045</galeid><sourcerecordid>A695364045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</originalsourceid><addsrcrecordid>eNptUk1v1DAQjRCIlsKVI4rEgcvu4o_YiS9I1YovqRIc4Gy59mTjEtvBTirtjb_Aif_HL2G2LAWkyrL8xn7zPGO_qnpKyYZ3ir0MIW8YYWxDmSTtveqUtoquOSHN_SNmSrUn1aNSrgiRggn1sDrhgnDVtfK0-rFNYTLZlxTr1NfzADX0Pdj5EOU0Q0wRahNdTX9--x5gHvYjggbnNEC8CeiKrfhKIpphzmbYu5ymffbOYyrq-ugW6-OutkNO0dv6o8lffMQrX5Ta-QKmAJLqkBYEITkYy-PqQW_GAk-O61n1-c3rT9t364sPb99vzy_WVgg6ry2jDePdpbLOSUaJYZQqyg2XjVOKSOaUa7m03FjROtoLZ0nDe8AHsFw4w8-qV791p-UygLMQsYNRT9kHk_c6Ga__P4l-0Lt0rbuOKEpbFHh-FMjp6wJl1ldpyRFr1kyyljeCMvWXtTMjaB_7hGI2-GL1uVQCyyWNQNbmDhYOB8Fb_Ije4_5dCTanUjL0t4VTog_-0OgPffCHvvEHJjz7t91b-h9D8F8nArwx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627345129</pqid></control><display><type>article</type><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</creator><creatorcontrib>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</creatorcontrib><description>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2022.12607</identifier><identifier>PMID: 35039876</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Animal models ; Animal models in research ; Animals ; Antibodies ; Antigens ; Avoidance Learning - physiology ; Blotting, Western ; Brain research ; Chronic Disease ; Development and progression ; Disease Models, Animal ; DNA-Binding Proteins - metabolism ; Dopamine receptors ; Dopaminergic Neurons - cytology ; Electron transport chain ; Enzymatic activity ; Experiments ; Exploratory behavior ; Glial fibrillary acidic protein ; Glial Fibrillary Acidic Protein - metabolism ; Humans ; Hydroxylase ; Immunofluorescence ; Immunohistochemistry ; Inflammation ; Laboratory animals ; Lewy bodies ; Locomotor activity ; Medical research ; Mice ; Mice, Inbred C57BL ; Mitochondria ; Motor Activity - physiology ; Movement disorders ; MPTP ; Neostriatum ; Nerve Tissue Proteins - metabolism ; Neurodegenerative diseases ; Neurological research ; Neurons ; Neurotoxic agents ; Older people ; Oxygen consumption ; Parkinson Disease, Secondary - chemically induced ; Parkinson Disease, Secondary - metabolism ; Parkinson Disease, Secondary - physiopathology ; Parkinson's disease ; Pathogenesis ; Rotenone ; Software ; Substantia nigra ; Substantia Nigra - cytology ; Synuclein ; Testing ; Tyrosine 3-Monooxygenase - metabolism ; Western blotting</subject><ispartof>Molecular medicine reports, 2022-03, Vol.25 (3), Article 91</ispartof><rights>COPYRIGHT 2022 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Zhang et al. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</citedby><cites>FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35039876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Sun, Bohao</creatorcontrib><creatorcontrib>Yang, Jifeng</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Li, Zhengzheng</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Hongzhi</creatorcontrib><creatorcontrib>Shen, Luxi</creatorcontrib><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</description><subject>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</subject><subject>Animal models</subject><subject>Animal models in research</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Avoidance Learning - physiology</subject><subject>Blotting, Western</subject><subject>Brain research</subject><subject>Chronic Disease</subject><subject>Development and progression</subject><subject>Disease Models, Animal</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Dopamine receptors</subject><subject>Dopaminergic Neurons - cytology</subject><subject>Electron transport chain</subject><subject>Enzymatic activity</subject><subject>Experiments</subject><subject>Exploratory behavior</subject><subject>Glial fibrillary acidic protein</subject><subject>Glial Fibrillary Acidic Protein - metabolism</subject><subject>Humans</subject><subject>Hydroxylase</subject><subject>Immunofluorescence</subject><subject>Immunohistochemistry</subject><subject>Inflammation</subject><subject>Laboratory animals</subject><subject>Lewy bodies</subject><subject>Locomotor activity</subject><subject>Medical research</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mitochondria</subject><subject>Motor Activity - physiology</subject><subject>Movement disorders</subject><subject>MPTP</subject><subject>Neostriatum</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neurodegenerative diseases</subject><subject>Neurological research</subject><subject>Neurons</subject><subject>Neurotoxic agents</subject><subject>Older people</subject><subject>Oxygen consumption</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Parkinson Disease, Secondary - metabolism</subject><subject>Parkinson Disease, Secondary - physiopathology</subject><subject>Parkinson's disease</subject><subject>Pathogenesis</subject><subject>Rotenone</subject><subject>Software</subject><subject>Substantia nigra</subject><subject>Substantia Nigra - cytology</subject><subject>Synuclein</subject><subject>Testing</subject><subject>Tyrosine 3-Monooxygenase - metabolism</subject><subject>Western blotting</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptUk1v1DAQjRCIlsKVI4rEgcvu4o_YiS9I1YovqRIc4Gy59mTjEtvBTirtjb_Aif_HL2G2LAWkyrL8xn7zPGO_qnpKyYZ3ir0MIW8YYWxDmSTtveqUtoquOSHN_SNmSrUn1aNSrgiRggn1sDrhgnDVtfK0-rFNYTLZlxTr1NfzADX0Pdj5EOU0Q0wRahNdTX9--x5gHvYjggbnNEC8CeiKrfhKIpphzmbYu5ymffbOYyrq-ugW6-OutkNO0dv6o8lffMQrX5Ta-QKmAJLqkBYEITkYy-PqQW_GAk-O61n1-c3rT9t364sPb99vzy_WVgg6ry2jDePdpbLOSUaJYZQqyg2XjVOKSOaUa7m03FjROtoLZ0nDe8AHsFw4w8-qV791p-UygLMQsYNRT9kHk_c6Ga__P4l-0Lt0rbuOKEpbFHh-FMjp6wJl1ldpyRFr1kyyljeCMvWXtTMjaB_7hGI2-GL1uVQCyyWNQNbmDhYOB8Fb_Ije4_5dCTanUjL0t4VTog_-0OgPffCHvvEHJjz7t91b-h9D8F8nArwx</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Zhang, Jing</creator><creator>Sun, Bohao</creator><creator>Yang, Jifeng</creator><creator>Chen, Zhuo</creator><creator>Li, Zhengzheng</creator><creator>Zhang, Nan</creator><creator>Li, Hongzhi</creator><creator>Shen, Luxi</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</title><author>Zhang, Jing ; Sun, Bohao ; Yang, Jifeng ; Chen, Zhuo ; Li, Zhengzheng ; Zhang, Nan ; Li, Hongzhi ; Shen, Luxi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-c214238b9cdd6210a211913a364d99062d9d736c3ac57d1f5dc043fe350c35da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</topic><topic>Animal models</topic><topic>Animal models in research</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Avoidance Learning - physiology</topic><topic>Blotting, Western</topic><topic>Brain research</topic><topic>Chronic Disease</topic><topic>Development and progression</topic><topic>Disease Models, Animal</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Dopamine receptors</topic><topic>Dopaminergic Neurons - cytology</topic><topic>Electron transport chain</topic><topic>Enzymatic activity</topic><topic>Experiments</topic><topic>Exploratory behavior</topic><topic>Glial fibrillary acidic protein</topic><topic>Glial Fibrillary Acidic Protein - metabolism</topic><topic>Humans</topic><topic>Hydroxylase</topic><topic>Immunofluorescence</topic><topic>Immunohistochemistry</topic><topic>Inflammation</topic><topic>Laboratory animals</topic><topic>Lewy bodies</topic><topic>Locomotor activity</topic><topic>Medical research</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mitochondria</topic><topic>Motor Activity - physiology</topic><topic>Movement disorders</topic><topic>MPTP</topic><topic>Neostriatum</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neurodegenerative diseases</topic><topic>Neurological research</topic><topic>Neurons</topic><topic>Neurotoxic agents</topic><topic>Older people</topic><topic>Oxygen consumption</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Parkinson Disease, Secondary - metabolism</topic><topic>Parkinson Disease, Secondary - physiopathology</topic><topic>Parkinson's disease</topic><topic>Pathogenesis</topic><topic>Rotenone</topic><topic>Software</topic><topic>Substantia nigra</topic><topic>Substantia Nigra - cytology</topic><topic>Synuclein</topic><topic>Testing</topic><topic>Tyrosine 3-Monooxygenase - metabolism</topic><topic>Western blotting</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Sun, Bohao</creatorcontrib><creatorcontrib>Yang, Jifeng</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Li, Zhengzheng</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Li, Hongzhi</creatorcontrib><creatorcontrib>Shen, Luxi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jing</au><au>Sun, Bohao</au><au>Yang, Jifeng</au><au>Chen, Zhuo</au><au>Li, Zhengzheng</au><au>Zhang, Nan</au><au>Li, Hongzhi</au><au>Shen, Luxi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>25</volume><issue>3</issue><artnum>91</artnum><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>35039876</pmid><doi>10.3892/mmr.2022.12607</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1791-2997
ispartof Molecular medicine reports, 2022-03, Vol.25 (3), Article 91
issn 1791-2997
1791-3004
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8809117
source Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Animal models
Animal models in research
Animals
Antibodies
Antigens
Avoidance Learning - physiology
Blotting, Western
Brain research
Chronic Disease
Development and progression
Disease Models, Animal
DNA-Binding Proteins - metabolism
Dopamine receptors
Dopaminergic Neurons - cytology
Electron transport chain
Enzymatic activity
Experiments
Exploratory behavior
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein - metabolism
Humans
Hydroxylase
Immunofluorescence
Immunohistochemistry
Inflammation
Laboratory animals
Lewy bodies
Locomotor activity
Medical research
Mice
Mice, Inbred C57BL
Mitochondria
Motor Activity - physiology
Movement disorders
MPTP
Neostriatum
Nerve Tissue Proteins - metabolism
Neurodegenerative diseases
Neurological research
Neurons
Neurotoxic agents
Older people
Oxygen consumption
Parkinson Disease, Secondary - chemically induced
Parkinson Disease, Secondary - metabolism
Parkinson Disease, Secondary - physiopathology
Parkinson's disease
Pathogenesis
Rotenone
Software
Substantia nigra
Substantia Nigra - cytology
Synuclein
Testing
Tyrosine 3-Monooxygenase - metabolism
Western blotting
title Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A11%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20effect%20of%20rotenone%20and%201%E2%80%91methyl%E2%80%914%E2%80%91phenyl%E2%80%911,2,3,6%E2%80%91tetrahydropyridine%20on%20inducing%20chronic%20Parkinson's%20disease%20in%20mouse%20models&rft.jtitle=Molecular%20medicine%20reports&rft.au=Zhang,%20Jing&rft.date=2022-03-01&rft.volume=25&rft.issue=3&rft.artnum=91&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2022.12607&rft_dat=%3Cgale_pubme%3EA695364045%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627345129&rft_id=info:pmid/35039876&rft_galeid=A695364045&rfr_iscdi=true